{
    "clinical_study": {
        "@rank": "122606", 
        "acronym": "TOMMY", 
        "arm_group": {
            "arm_group_label": "Total BM irradiation dose", 
            "arm_group_type": "Experimental", 
            "description": "Total Bone Marrow Irradiation (TBMI) is delivered by the Tomotherapy HI-ART machine, in 2 fractions per day during 4 consecutive days from d -6 to d -3. The escalated dose levels are determined according to a \"3x3\" modified Fibonacci method and five dose levels will be explored. The doses per fraction are: 1gy, 1.25gy, 1.5gy, 1.75gy and 2gy, and consequently the cumulative TBMI doses are:  8gy, 10gy, 12gy, 14gy and 16gy.\nFor Every patients:\nDrug : Melphalan is infused intravenously in 30 minutes on day -2 after IV anti-emetics.\nAutologous Peripheral Stem Cell Rescue : are re-infused in the central line on day \"0\" after adequate premedication."
        }, 
        "brief_summary": {
            "textblock": "In Multiple Myeloma, an adult hematological malignancy, mainly located in the Bone Marrow\n      (BM), dramatic recent progresses have been observed, thanks to new agents (proteasome\n      inhibitors and IMIDs). However, at time of first relapse, high-dose therapy followed by Stem\n      Cell Rescue (SCR) is frequently mandatory as a consolidation in minimal residual disease, to\n      healthy patients under 65 yo, combining Melphalan (MPH) and/or Total Body Irradiation.\n      Modern irradiation modalities are now available by the use of HI-ART Tomotherapy system to\n      realize a Total Bone Marrow Irradiation (TBMI), in order both to limit the dose administered\n      to Organ at Risk (lungs, oral cavity) and to focus efficacy on BM. In this phase-1 study,\n      the conditioning regimen before SCR will combine a fixed high-dose MPH (140 mg/m\u00b2) and a\n      dose escalated TBMI, so as to define its Maximal Tolerated Dose (MTD) and the Dose Limiting\n      Toxicities (DLT). An extended cohort will further in a phase-2 setting."
        }, 
        "brief_title": "Phase 1-2 Study of Total Bone Marrow Irradiation With Helicoidal Tomotherapy in 1st Myeloma Relapse", 
        "completion_date": {
            "#text": "January 2017", 
            "@type": "Anticipated"
        }, 
        "condition": "Multiple Myeloma in Relapse", 
        "condition_browse": {
            "mesh_term": [
                "Multiple Myeloma", 
                "Neoplasms, Plasma Cell", 
                "Recurrence"
            ]
        }, 
        "detailed_description": {
            "textblock": "Experimental :\n\n      Total Bone Marrow Irradiation (TBMI) is delivered by the Tomotherapy HI-ART machine, in 2\n      fractions per day during 4 consecutive days from d -6 to d -3. The escalated dose levels are\n      determined according to a \"3x3\" modified Fibonacci method and five dose levels will be\n      explored. The doses per fraction are: 1gy, 1.25gy, 1.5gy, 1.75gy and 2gy, and consequently\n      the cumulative TBMI doses are:  8gy, 10gy, 12gy, 14gy and 16gy.\n\n      Drug : Melphalan is infused intravenously in 30 minutes on day -2 after IV anti-emetics.\n\n      Autologous Peripheral Stem Cell Rescue : are re-infused in the central line on day \"0\" after\n      adequate premedication.\n\n      Despite the recent finding of new drugs (proteasome inhibitors and IMIDs), Multiple Myeloma\n      still remain uncurable, especially after the first relapse, even in responding disease under\n      conventional chemotherapy. In the healthy youngest patients (<65 yo), when peripheral stem\n      cells collection is available, a high-dose therapy is often proposed in consolidation of\n      complete or very good partial remission: the conditioning regimen usually includes high dose\n      alkylating agent (mostly Melphalan) and/or Total Body Irradiation. The new Tomotherapy\n      HI-ART technology allows irradiating on a 1.6m length field all the bone marrow sites\n      together with optimal respect of the Organ at Risk (lungs, oral cavity, heart, liver,\n      kidneys\u2026). The proposed phase-1 study will explore the safety and efficacy of escalated dose\n      of Total Bone-Marrow Irradiation in combination with a fixed dose of Melphalan (140mg/m\u00b2),\n      followed by autologous SCR. To determine the MTD is the main objective of the study, then\n      the toxicity profile (DLTs) and the RP2D in an extended cohort at the MTD dose."
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Multiple Myeloma in first relapse.\n\n          -  In Complete or very good partial remission\n\n          -  Available Collected Autologous Peripheral Stem cells: 2.5x106 CD34+/Kg\n\n        Exclusion Criteria:\n\n          -  Uncontrolled visceral disease: kidney, heart, lung, diabetes mellitus\n\n          -  Previous Total body irradiation\n\n          -  Any previous radiation dose to the spinal cord which could reach to 45gy equivalent,\n             including the proposed TBMI\n\n          -  Amyloidosis\n\n          -  Brain localizations"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "65 Years", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "44", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "February 15, 2013", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01794572", 
            "org_study_id": "ICO-2012-04", 
            "secondary_id": "2012-001473-91"
        }, 
        "intervention": [
            {
                "arm_group_label": "Total BM irradiation dose", 
                "description": "Melphalan: 140 mg/m\u00b2is infused intravenously in 30 minutes on day -2 after IV anti-emetics (5-HT3 antagonists).", 
                "intervention_name": "Melphalan", 
                "intervention_type": "Drug", 
                "other_name": "Phenylalanin Mustard"
            }, 
            {
                "arm_group_label": "Total BM irradiation dose", 
                "description": "Autologous Peripheral Stem Cell Rescue : 2.5 10^6 CD-34/Kg are re-infused in the central line on day \"0\" after adequate premedication.", 
                "intervention_name": "Autologous Hematopoietic Stem cell", 
                "intervention_type": "Biological", 
                "other_name": "Hematopoietic stem cell"
            }
        ], 
        "intervention_browse": {
            "mesh_term": "Melphalan"
        }, 
        "is_fda_regulated": "No", 
        "keyword": [
            "Multiple Myeloma", 
            "Relapse", 
            "Complete Remission", 
            "Very Good Partial Remission"
        ], 
        "lastchanged_date": "February 19, 2013", 
        "location": [
            {
                "contact": {
                    "email": "gerald.marit@chu-bordeaux.fr", 
                    "last_name": "Gerald Marit, MD, PhD", 
                    "phone": "+33 556795679"
                }, 
                "facility": {
                    "address": {
                        "city": "Bordeaux", 
                        "country": "France", 
                        "zip": "33604"
                    }, 
                    "name": "CHU Haut-Leveque, service d'H\u00e9matologie"
                }, 
                "investigator": {
                    "last_name": "Gerald Marit, MD, PhD", 
                    "role": "Principal Investigator"
                }, 
                "status": "Not yet recruiting"
            }, 
            {
                "contact": {
                    "email": "b.henriques@bordeaux.unicancer.fr", 
                    "last_name": "Benedicte Henriques de Figueiredo, MD", 
                    "phone": "+33 556333366"
                }, 
                "facility": {
                    "address": {
                        "city": "Bordeaux", 
                        "country": "France", 
                        "zip": "33076"
                    }, 
                    "name": "CLCC Bergonie, service de radiotherapie"
                }, 
                "investigator": {
                    "last_name": "Benedicte Henriques de Figueriredo, MD", 
                    "role": "Principal Investigator"
                }, 
                "status": "Not yet recruiting"
            }, 
            {
                "contact": {
                    "email": "thierry.facon@chru.lille.fr", 
                    "last_name": "Thierry Facon, MD, PhD", 
                    "phone": "+33 320445962"
                }, 
                "facility": {
                    "address": {
                        "city": "Lille", 
                        "country": "France", 
                        "zip": "59037"
                    }, 
                    "name": "CHU Claude Huriez, service d'h\u00e9matologie"
                }, 
                "investigator": {
                    "last_name": "Thierry Facon, MD, PhD", 
                    "role": "Principal Investigator"
                }, 
                "status": "Recruiting"
            }, 
            {
                "contact": {
                    "email": "e-lartigau@o-lambret.fr", 
                    "last_name": "Eric Lartigau, MD, PhD", 
                    "phone": "+33 320295911"
                }, 
                "facility": {
                    "address": {
                        "city": "Lille", 
                        "country": "France", 
                        "zip": "59020"
                    }, 
                    "name": "CLCC Oscar Lambret, service de radioth\u00e9rapie"
                }, 
                "investigator": {
                    "last_name": "Eric Lartigau, MD, PhD", 
                    "role": "Principal Investigator"
                }, 
                "status": "Recruiting"
            }, 
            {
                "contact": {
                    "email": "philippe.moreau@chu-nantes.fr", 
                    "last_name": "Philippe Moreau, MD, PhD", 
                    "phone": "+33 240083260"
                }, 
                "facility": {
                    "address": {
                        "city": "Nantes", 
                        "country": "France", 
                        "zip": "44093"
                    }, 
                    "name": "CHU Hotel-Dieu, service d'h\u00e9matologie"
                }, 
                "investigator": {
                    "last_name": "Philippe Moreau, MD, PhD", 
                    "role": "Principal Investigator"
                }, 
                "status": "Recruiting"
            }, 
            {
                "contact": {
                    "email": "marc-andre.mahe@ico.unicancer.fr", 
                    "last_name": "Marc A Mah\u00e9, MD, PhD", 
                    "phone": "+33 240679900"
                }, 
                "facility": {
                    "address": {
                        "city": "Nantes, St Herblain", 
                        "country": "France", 
                        "zip": "44805"
                    }, 
                    "name": "CLCC ICO, service de radioth\u00e9rapie"
                }, 
                "investigator": {
                    "last_name": "Marc A Mah\u00e9, MD, PhD", 
                    "role": "Principal Investigator"
                }, 
                "status": "Recruiting"
            }, 
            {
                "contact": {
                    "email": "gnoel@strasbourg.fr", 
                    "last_name": "Georges Noel, MD, PhD", 
                    "phone": "+33 88252478"
                }, 
                "facility": {
                    "address": {
                        "city": "Strasbourg", 
                        "country": "France", 
                        "zip": "67091"
                    }, 
                    "name": "CLCC Paul Strauss, service de radioth\u00e9rapie"
                }, 
                "investigator": {
                    "last_name": "Gerard Noel, MD, PhD", 
                    "role": "Principal Investigator"
                }, 
                "status": "Recruiting"
            }, 
            {
                "contact": {
                    "email": "bruno.lioure@chru-strasbourg.fr", 
                    "last_name": "Bruno Lioure, MD, PhD", 
                    "phone": "+33 88 127676"
                }, 
                "facility": {
                    "address": {
                        "city": "Strasbourg", 
                        "country": "France", 
                        "zip": "67098"
                    }, 
                    "name": "CHU Hautepierre, service d'h\u00e9matologie"
                }, 
                "investigator": {
                    "last_name": "Bruno Lioure, MD, PhD", 
                    "role": "Principal Investigator"
                }, 
                "status": "Recruiting"
            }
        ], 
        "location_countries": {
            "country": "France"
        }, 
        "number_of_arms": "1", 
        "official_title": "Phase 1-2 Study of the Combination of Escalated Total Bone Marrow Irradiation (TBMI) by Helicoidal Tomotherapy and a Fixed High-dose Melphalan (140 mg/m\u00b2) Followed by Peripheral Stem Cell Rescue (PSC) in First Relapsed Multiple Myeloma.", 
        "other_outcome": {
            "description": "Bone-marrow control evaluation by FDG PET-Scan Disease-free survival at 1 year and Overall Survival", 
            "measure": "Efficacy", 
            "safety_issue": "No", 
            "time_frame": "1 and 2 years"
        }, 
        "overall_contact": {
            "email": "marc-andre.mahe@ico.unicancer.fr", 
            "last_name": "Marc A MAHE, MD, PhD", 
            "phone": "+33 240679900"
        }, 
        "overall_contact_backup": {
            "email": "francois.pein@ico.unicancer.fr", 
            "last_name": "Francois JL PEIN, MD", 
            "phone": "+33 240679908"
        }, 
        "overall_official": [
            {
                "affiliation": "Institut de Cancerologie de l'Ouest", 
                "last_name": "Marc A MAHE, MD, PhD", 
                "role": "Principal Investigator"
            }, 
            {
                "affiliation": "University Hospital, CHU de NANTES", 
                "last_name": "Philippe MOREAU, MD, PhD", 
                "role": "Principal Investigator"
            }
        ], 
        "overall_status": "Recruiting", 
        "oversight_info": {
            "authority": "France: Agence Nationale de S\u00e9curit\u00e9 du M\u00e9dicament et des produits de sant\u00e9", 
            "has_dmc": "Yes"
        }, 
        "phase": "Phase 1/Phase 2", 
        "primary_completion_date": {
            "#text": "January 2015", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "description": "Maximal Tolerated Dose Type of Dose-limiting Toxicities The escalated dose levels are determined according to a \"3x3\" modified Fibonacci method and five dose levels will be explored. The doses per fraction are: 1gy, 1.25gy, 1.5gy, 1.75gy and 2gy, and consequently the cumulative TBMI doses are:  8gy, 10gy, 12gy, 14gy and 16gy.", 
            "measure": "Maximal Tolerated Dose, type of DLTs", 
            "safety_issue": "Yes", 
            "time_frame": "1 year"
        }, 
        "reference": [
            {
                "PMID": "18786784", 
                "citation": "Wong JY, Rosenthal J, Liu A, Schultheiss T, Forman S, Somlo G. Image-guided total-marrow irradiation using helical tomotherapy in patients with multiple myeloma and acute leukemia undergoing hematopoietic cell transplantation. Int J Radiat Oncol Biol Phys. 2009 Jan 1;73(1):273-9. doi: 10.1016/j.ijrobp.2008.04.071. Epub 2008 Sep 9."
            }, 
            {
                "PMID": "21047977", 
                "citation": "Somlo G, Spielberger R, Frankel P, Karanes C, Krishnan A, Parker P, Popplewell L, Sahebi F, Kogut N, Snyder D, Liu A, Schultheiss T, Forman S, Wong JY. Total marrow irradiation: a new ablative regimen as part of tandem autologous stem cell transplantation for patients with multiple myeloma. Clin Cancer Res. 2011 Jan 1;17(1):174-82. Epub 2010 Nov 3."
            }
        ], 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01794572"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": {
            "description": "Safety profile: acute, short and middle term toxicities Recommended Dose for Phase-2 (RDP2) and Extended Cohort for 14 patients at this dose", 
            "measure": "Safety profile Recommended Dose for Phase-2 (RDP2)", 
            "safety_issue": "Yes", 
            "time_frame": "1 year"
        }, 
        "source": "Institut Cancerologie de l'Ouest", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Institut Cancerologie de l'Ouest", 
                "agency_class": "Other"
            }
        }, 
        "start_date": "January 2013", 
        "study_design": "Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "February 2013"
    }
}